Intrinsic Bioprobes Inc. (IBI) is a privately held biotechnology company that develops innovative technologies for rapid and sensitive proteomics and biomarker analysis. IBI applies its innovations through protein analysis services and research partnerships. Organizations working with IBI can accelerate their drug development cycles, increase the efficacy of therapies in development, and reduce bottom line expenses. The company's proprietary technologies consist of Bioreactive Mass Spectrometer Probes (BRP™), simple devices for rapid, sensitive and accurate protein characterization, and Mass Spectrometric Immunoassay (MSIA™), a high-performance approach for the selective isolation of proteins from complex biological matrices. These root technologies are incorporated into the MASSAY™ Integrated System, a high throughput mass spectrometry approach geared for proteome characterization.